This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Jublia

Valeant Pharmaceuticals International, Inc.

Drug Names(s): efinaconazole, KP-103, IDP-108

Description: IDP-108 is a topical triazole antifungal.

Triazole antifungals inhibit the fungal cytochrome P450 enzyme 14alpha-demethlyase, thus preventing the conversion of lanosterol to ergosterol, an essential component of the fungal cytoplasmic membrane.

Deal Structure: IDP-108 was licensed by Dow Pharmaceutical Sciences from Kaken Pharmaceuticals.

In January 2010, Valeant acquired Dow Pharmaceutical Sciences. Dow Pharmaceutical will operate as a wholly owned subsidiary of Valeant. Kaken retained rights to the compound in Japan.

Partners: Kaken Pharmaceutical Company, Ltd


Jublia News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug